Dermatology drug developer raises $16M

Article

Thesan Pharmaceuticals has been given $16 million in series A funding to develop novel treatments for inflammatory skin disorders.

Related Videos
Related Content

Derm In The News: September 17-23

September 23rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

CeraVe Partners With George Washington University to Expand Residency Training Program

September 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Combination Treatments in HS Require Further Review

September 22nd 2023

Frontline Forum Part 4: Improving Basal Cell Carcinoma Management

September 22nd 2023

Derm In The News: September 17-23

September 23rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

CeraVe Partners With George Washington University to Expand Residency Training Program

September 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Combination Treatments in HS Require Further Review

September 22nd 2023

Frontline Forum Part 4: Improving Basal Cell Carcinoma Management

September 22nd 2023

Derm In The News: September 17-23

September 23rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

CeraVe Partners With George Washington University to Expand Residency Training Program

September 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Combination Treatments in HS Require Further Review

September 22nd 2023

Frontline Forum Part 4: Improving Basal Cell Carcinoma Management

September 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.